AstraZeneca’s growth engine stays on track despite cost pressures

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN)  full-year results showed the pharmaceutical radical navigating a challenging examination play with a robust operational show and a renewed committedness to semipermanent growth, analysts said.

Fourth-quarter gross came successful astatine $15.5 billion, 2% up astatine changeless speech rates and conscionable implicit 1% supra consensus.

Core net per stock were successful enactment astatine $2.12, though Shore Capital estimates underlying net maturation of person to 16% for the twelvemonth erstwhile the interaction of non-repeating collaboration gross is stripped out.

Oncology continued to beryllium a agleam spot, with income up 19% astatine changeless speech rates to $6.47 billion, underpinned by beardown contributions from Imfinzi and Calquence. Alliance gross besides bushed expectations, buoyed by request for Enhertu.

Cardiovascular, renal and metabolism (CVRM) besides exceeded forecasts, but Shore noted that Farxiga, AstraZeneca’s top-selling product, is expected to travel nether generic unit from the 2nd 4th of 2026.

Despite these top-line beats, halfway operating nett fell abbreviated of statement by 8% arsenic R&D and SG&A expenses came successful higher than expected.

R&D unsocial accounted for 24% of full revenue, somewhat supra anterior guidance, reflecting concern successful late-stage trials and next-generation technologies, including GLP-1s and bispecifics.

Looking ahead, AZ issued guidance for mid- to high-single-digit gross maturation successful 2026 and debased double-digit EPS growth, some astatine changeless speech rates.

While statement forecasts for 2026 look to beryllium broadly successful enactment with consensus, ShoreCap's ain forecast (11% gross and 19% EPS growth) sits supra guidance and whitethorn beryllium revised somewhat to bespeak higher concern costs.

Importantly, AstraZeneca reiterated its ambition to execute $80 cardinal successful yearly gross by 2030, a people Shore believes is achievable and perchance beatable, projecting $82 cardinal implicit the aforesaid horizon.

Valuation-wise, the banal trades astatine a guardant price-to-earnings ratio of 18–19 times for 2026, a premium to peers but justified by what Shore calls “an enviable pipeline and wide blockbuster base” with aggregate signifier III catalysts expected again this year.

After a sluggish start, the shares were up 1% at 14,044p.